leuprorelin sandoz
sandoz new zealand limited - leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg - subcutaneous implant - 5 mg - active: leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg excipient: poly(lactide) - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma
leuprorelin sandoz
sandoz new zealand limited - leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin - subcutaneous implant - 3.6 mg - active: leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin excipient: polyglactin - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma
lucrin leuprorelin acetate 5mg/ml injection multidose vial
abbvie pty ltd - leuprorelin acetate -
eligard leuprorelin acetate 45 mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 45 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.,central precocious puberty (cpp),eligard 45mg 6 month is indicated for the treatment of children 2 years of age and older with central precocious puberty (cpp).
lucrin depot leuprorelin acetate 45mg powder for suspension prefilled dual-chamber syringe injection
abbvie pty ltd - leuprorelin acetate, quantity: 45 mg - injection - excipient ingredients: mannitol; polylactic acid; stearic acid; glacial acetic acid; carmellose sodium; polysorbate 80; water for injections - lucrin depot is indicated for the palliative treatment of metastatic or locally advanced prostate cancer.
lucrin depot paediatric leuprorelin acetate 30 mg powder for injection prefilled dual chamber syringe
abbvie pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: mannitol; polylactic acid - lucrin depot paediatric 30 mg 3-month pds injection is indicated in the treatment of children with central precocious puberty (cpp).
lucrin depot 4-month leuprorelin acetate 30mg powder for injection prefilled dual-chamber syringe with 23 g needle
abbvie pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: mannitol; polylactic acid - in the palliative treatment of metastatic or locally extensive prostate cancer (stage c and d).
leuprorelin 1-month depot 3.75 mg powder and solvent for prolonged-release suspension for injection
gp-pharm, s.a. - leuprorelin acetate - pdr+solv for pr for susp for inj - 3.75 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
leuprorelin 3-month depot 22.5mg powder and solvent for prolonged-release suspension for injection
gp-pharm, s.a. - leuprorelin acetate - pdr+solv for pr for susp for inj - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin - endocrine therapy. hormones and related agents. gonadotropin-releasing hormones - it is indicated for palliative treatment of hormone dependent advanced prostate cancer.
eligard leuprorelin acetate 30mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.